Sjögren Syndrome with CNS Vasculitis: What to Do When Glucocorticoids and Cyclophosphamide Have Not Controlled Disease Activity

Clinical Scenario

This protocol addresses Sjögren syndrome with active systemic disease and central nervous system vasculitis — a severe manifestation that may present as cerebral vasculitis with focal deficit, myelitis, meningoencephalitis, or demyelinating disease with motor deficit.

Previous Treatment — Escalation Trigger

This is a next-line protocol. It applies when a first-line regimen of glucocorticoids (intravenous methylprednisolone pulses followed by oral glucocorticoids) combined with cyclophosphamide pulses has not achieved the required therapeutic response — specifically, a reduction of ≥3 points in the global ESSDAI score.

Next-Line Approach (Partial)

Escalation in this refractory setting involves rituximab. The complete administration schedule and monitoring details are available in the structured protocol below.

Treatment Goal

The defined therapeutic target is a reduction of ≥3 points in the global ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) score — the same endpoint the prior line did not reach.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Demyelinating disease with motor deficit; cerebral vasculitis presenting with focal deficit; myelitis; meningoencephalitis.

The use of rituximab may be considered in patients with severe, refractory systemic disease.

With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.

View source ↗